1. Scrip
  2. >>New Products

Sunovion Plans September Launch For Parkinson’s 'Off' Episode Drug Kynmobi

 
• By Mandy Jackson

Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.

Close Up Of Senior Man Suffering With Parkinsons Diesease
Tremors, stiffness and other motor symptoms emerge during off episodes • Source: Shutterstock

Sunovion Pharmaceuticals Inc. plans to launch Kynmobi (apomorphine hydrochloride) sublingual film for the on-demand treatment of “off” episodes in Parkinson’s disease in September following US Food and Drug Administration approval of the product on 21 May. By then, social distancing requirements to prevent the transmission of COVID-19 may have eased enough for sales representatives to market the drug through in-person meetings with prescribers.

Sunovion president and CEO Antony Loebel told Scrip that the Sumitomo Dainippon Pharma Co. Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.